Source: Financial Modeling Prep · peers by sector/industry
Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Valuation
Trading at 2.2× sales vs its 20.4× historical median P/S.
Fair value ≈ $14.46 · price $1.54 today
Undervalued · 89% below
Loading valuation…
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
IVDA is one of the only low-float stocks tied to AI surveillance, autonomous drones, and threat detection.
If you think robotics, safety, and government tech will scale, you’re looking at one of the earliest and cheapest ways to play it.
Zero hype. Max upside.
$EYEN $PALI $LGVN $QNRX $NGM
$NGM NGM Biopharmaceuticals, Inc. (NASDAQ:NGM): A Promising Biotech Tackling Unmet Medical Needs https://beyondspx.com/article/ngm-biopharmaceuticals-inc-nasdaq-ngm-a-promising-biotech-tackling-unmet-medical-needs
$NGM NGM Biopharmaceuticals, Inc. (NASDAQ:NGM): A Promising Biotech Tackling Unmet Medical Needs http://beyondspx.com/2024/08/05/ngm-biopharmaceuticals-inc-nasdaqngm-a-promising-biotech-tackling-unmet-medical-needs/
$NGM And that was that. There’s obviously things going on here that are way above my head. Time will tell exactly what, but I’m sure TCG and affiliates will be more than happy when payday comes.
$NGM
Any law firm which responds to this solicitation, I have information which may be relevant to your claims.
Message me and my attorney will contact you….
$NGM NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting
https://www.stocktitan.net/news/NGM/ngm-bio-to-present-two-posters-highlighting-clinical-data-from-the-6kycxr7ga5ij.html
